Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 8/20 | 0.54 |
| ▸ | RIPK3 | Q9Y572 | 8/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.37 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15124156 | 0.91 | CSNK1E (0.50) | CSNK1ERIPK3NMT1DPP4 | |
| SCHEMBL3722445 | 0.87 | CSNK1E (0.56) | CSNK1ERIPK3TLR9TLR8TLR7 | |
| SCHEMBL3723007 | 0.86 | RIPK3 (0.43) | CSNK1ERIPK3 | |
| SCHEMBL3115717 | 0.82 | CSNK1E (0.60) | CSNK1ERIPK3TLR9TLR8TLR7 | |
| SCHEMBL3114184 | 0.82 | CSNK1E (0.57) | CSNK1ERIPK3TLR9TLR8TLR7 | |
| SCHEMBL3723163 | 0.81 | CSNK1E (0.57) | CSNK1ERIPK3 | |
| SCHEMBL477144 | 0.81 | CSNK1E (0.60) | CSNK1ERIPK3TLR9TLR8TLR7 | |
| SCHEMBL477042 | 0.79 | CSNK1E (0.60) | CSNK1ERIPK3TLR9TLR8TLR7 | |
| SCHEMBL3724669 | 0.79 | CSNK1E (0.53) | CSNK1ERIPK3NMT1DPP4 | |
| SCHEMBL477183 | 0.78 | CSNK1E (0.59) | CSNK1ERIPK3TLR9TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130190314-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-07-25 | — | — | US | disclosed |
| US-20130190314-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-07-25 | — | — | US | disclosed |
| US-20130190314-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2013-07-25 | — | — | US | disclosed |
| EP-2398802-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI (FR) | 2011-12-28 | — | — | EP | disclosed |
| WO-2010070237-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010070237-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE, PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190314-A1 | DERIVATIVES OF 6-CYCLOAMINO-2-THIENYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE AND 6-CYCLOAMINO-2-FURANYL-3-(PYRIDIN-4-YL)IMIDAZO[1,2-b]-PYRIDAZINE, PREPARATION AND THERAPEUTIC USE THEREOF | CSNK2A1, CSNK1A1, CSNK2A2 | CSNK1E 11/4885RIPK3 1086/4885TLR9 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.